Chemomab Therapeutics Ltd - AD - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CMMB Nasdaq 8731 https://www.chemomab.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Chemomab Therapeutics Ltd - AD

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 - Apr 2nd, 2024 11:00 am
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis - Mar 25th, 2024 11:06 am
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update - Mar 7th, 2024 12:00 pm
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference - Mar 5th, 2024 12:00 pm
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases - Feb 20th, 2024 12:00 pm
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update - Feb 14th, 2024 12:00 pm
Chemomab Therapeutics to Participate in Upcoming Investor Conferences - Feb 5th, 2024 12:00 pm
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis - Jan 30th, 2024 12:00 pm
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 - Jan 3rd, 2024 12:00 pm
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis - Nov 16th, 2023 12:00 pm
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis - Nov 15th, 2023 12:00 pm
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023 - Nov 13th, 2023 1:00 pm
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Nov 9th, 2023 1:00 pm
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement - Nov 6th, 2023 9:15 pm
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update - Oct 30th, 2023 11:00 am
Chemomab Therapeutics to Present at Upcoming Scientific Conferences - Oct 26th, 2023 11:00 am
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference - Sep 28th, 2023 11:00 am
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Aug 29th, 2023 11:00 am
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update - Aug 14th, 2023 12:00 pm
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis - Jun 28th, 2023 11:00 am